Europe, the rare neurological disease treatment market, is anticipated to reach US$ 3,763.41 Mn in 2027 from US$ 2,048.10 Mn in 2019 – GlobeNewswire

Posted on by

New York, May 21, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Rare Neurological Disease Treatment Market to 2027 - Regional Analysis and Forecasts by Indication ; Drug Type ; Distribution Channel ; Mode of Administration and Country" - https://www.reportlinker.com/p05894548/?utm_source=GNW Restraining factors, such as higher cost of rare neurological disease treatments likely to damage the growth of the market in the coming years.

On the other hand, artificial intelligence for the treatment of rare neurological diseases is expected to have a positive impact on the growth of the Europe rare neurological disease treatment market in the coming years. A large group of rare diseases that have inefficient diagnoses and treatments are the neurological disease.These diseases target the nervous system, which include the brain, spinal cord, and all the nerves that run throughout the human body.

There is no surety regarding the onset of the diseases; some can strike during childhood, whereas others can affect even highly aged people. In the world of medicine, rare neurological diseases represent significant burden on health systems in terms of disease diagnosis, treatment, and management.Some of the majorly observed rare neurological diseases comprises narcolepsy, amyotrophic lateral sclerosis, Alzheimers disease, multiple sclerosis, spinal muscular atrophy (SMA), Duchenne muscular dystrophy, and others.

According to a data published by World Health Organisation (WHO), it is estimated that about 30 million Europeans in 27 EU-countries suffer from a rare disease. Over the past few decades, various research and developmental works have been carried out pertaining to the diagnosis and management of rare neurological diseases.Advancements in healthcare systems and modernizing diagnostic systems are likely to enhance the screening operation for rare neurological diseases.

Additionally, increasing prevalence of rare neurological diseases is expected to drive the growth of the rare neurological disease treatment market during the forecast period. In 2019, the Alzheimers disease accounted for the largest market share in the Europe rare neurological disease treatment market.Alzheimers disease is a progressive disease and a type of dementia, and the condition is characterized by eating and death of brain cells.

It is characterized by symptoms such as reduced thinking, memory loss, and lacking behavioural sense.These symptoms get worse over time and highly reduce the independently for daily routine.

The disease accounts for nearly 60% to 80% of all dementia cases.It is widely seen among the aging population.

In Germany, more than 1.5 million people are living with Alzheimers disease. For instance, In 2012, Alzheimers Europe reports that 1,572,104 individuals with dementia were in Germany. This constitutes 1.92 per cent of the total 81,990,837 population. The number of people with dementia is marginally higher than the EU average of 1.55 per cent. In 2019, the biologics segment, held the most significant market share of the rare neurological disease treatment market by the drug type.This segment is also anticipated to be the fastest growing segment of the market in 2027, owing to the increasing neurological disorders, coupled with increasing robust hospital infrastructure and advancements in medicines, has enabled people for various treatments for the deadliest diseases.

Hence, the segment is anticipated to witness growth at a significant rate during the forecast period. Some of the significant primary and secondary sources for cold plasma equipment included in the report are World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA) and National Institute of Health (NIH)Read the full report: https://www.reportlinker.com/p05894548/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

View post:
Europe, the rare neurological disease treatment market, is anticipated to reach US$ 3,763.41 Mn in 2027 from US$ 2,048.10 Mn in 2019 - GlobeNewswire

Chronic Kidney Disease is Associated With Intracranial Atherosclerotic Disease – Neurology Advisor

Posted on by

Chronic kidney disease (CKD), defined as either a reduced kidney function based on estimated glomerular filtration rate (eGFR) and cystatin C (CysC) or the presence of kidney damage, is associated with an increased risk for intracranial atherosclerotic disease (ICAD), according to study results published in Neurology.

Previous studies have reported an increased risk for cardiovascular morbidity and mortality among patients with CKD, but limited data are available on the association between CKD and ICAD and whether the association between CKD and extracranial atherosclerosis can be generalized to intracranial arteries. The goal of the current study was to explore the association between reduced kidney function and kidney damage with ICAD.

The researchers used data from the Atherosclerosis Risk in Communities (ARIC) study and included data on kidney function measurements and 3-dimensional vessel wall MRI. This technique is able to characterize intracranial plaques as well as the severity of stenosis and serves as an effective tool for assessing ICAD.

The associations between kidney measures and ICAD status were analyzed in binomial (presence vs absence of ICAD, presence vs absence of detectable stenosis) and multinomial (0 vs 1 and 0 vs 2 plaques, absent or mild stenosis vs 50%70% and >70% stenosis or occlusion). The main outcomes were presence of intracranial plaques and luminal stenosis.

The analysis included 1762 participants (mean age 76.3 years, 41.5% men) who received MRI scans with good vessel wall image quality and with available kidney measures. Most patients (63.7%) did not have a plaque on vessel wall MRI; 293 (16.6%) had 1 plaque; and 347 (19.7%) had multiple (2) plaques. Among 640 participants with at least 1 plaque, 189 (29.5%) had 1 plaque causing 50% stenosis, and 944 (14.7%) had 1 plaque causing >70% stenosis or occlusion.

A total of 51.7% of participants with plaques and 42.2% of those without plaques had eGFR based on CysC (eGFRcysc) <60 mL/min/1.73 m2. The risk for ICAD was significantly increased for patients with reduced kidney function, compared to those with normal kidney function (adjusted odds ratio [aOR] 1.29; 95% CI, 1.04-1.60). Furthermore, eGFRcysc <60 mL/min/1.73 m2 was associated with presence of any detectable stenosis (aOR 1.31; 95% CI 1.04-1.63) and with the presence of >70% stenosis or occlusion independently (OR 2.15; 95% CI 1.32-3.50) but not with lesser degrees of stenosis.

In adjusted multinomial logistic regression models, eGFRcysc <60 mL/min/1.73 m2 was associated with a 41% increased risk for having a single plaque (aOR 1.41; 95% CI, 1.06-1.87), compared to no plaque, but there was no significantly increased risk for multiple plaques.

While elevated albumin-to-creatinine ratio (ACR) or CysC did not show significant associations with plaque presence when assessed as continuous variables, in multinomial logistic regression models, albuminuria was associated with presence of 50% to 70% stenosis with an adjusted OR of 2.01 (95% CI 1.143.55) for ACR 30 (vs <30) and 2.88 (95% CI 1.038.10) for ACR 300 (vs <300). CysC was associated with presence of >70% stenosis or occlusion independently (aOR 3.16; 95% CI 1.446.94).

The study had several limitations, according to the researchers, including the cross-sectional design, inclusion of relatively healthy, and small number of subjects with significant stenosis.

Our study revealed that CKD is associated with ICAD in a subset of participants in the ARIC cohort. Thus, kidney disease should be considered an important factor in risk stratification for cerebrovascular disease, concluded the researchers.

Reference

Hao Q, Gottesman RF, Qiao Y, et al. Association between kidney disease measures and intracranial atherosclerosis: The ARIC study [published online ahead of print, 2020 Apr 17]. Neurology. doi:10.1212/WNL.0000000000009311

Read more here:
Chronic Kidney Disease is Associated With Intracranial Atherosclerotic Disease - Neurology Advisor

Epilepsy and COVID-19: Connection and Considerations – Neurology Advisor

Posted on by

The effect of epilepsy on coronavirus disease 2019 (COVID-19), and vice versa, have been little explored. In a brief communication published in Epilepsy and Behavior, Naoto Kuroda, MD, from Wayne State University, provided information about the associations between, and the considerations for, COVID-19 and epilepsy.

While associations between COVID-19 and epilepsy have not been reported, the Centers for Disease Control and Prevention indicate that epilepsy, among other neurological comorbidities, may be a risk factor for the disease. This is in direct contrast to current medical knowledge and literature, all of which lack data to support an association between epilepsy and a higher risk of COVID-19. However, patients with epilepsy who smoke or have diabetes, cancer, lung disease, or obesity may be at an increased risk.

In addition, the effects of COVID-19 on epilepsy are unclear. It is likely that COVID-19 may cause fever in patients with epilepsy, and this fever may in turn trigger seizures. Symptoms of COVID-19, which are primarily respiratory and gastrointestinal in nature, have not shown any impact on seizure related symptoms in patients with epilepsy.

Future treatment of COVID-19 may impact epilepsy, particularly in terms of drug-drug interactions. Drugs that are being considered for COVID-19 treatment must be considered in relation to how they may interact with anti-epileptic drugs (AEDs). Currently, levetiracetam is of interest for patients with epilepsy as it does not appear to interact with any potential COVID-19 medication.

While some epilepsy medications may affect the immune system (eg, steroids), Dr Kuroda suggests that there is evidence that treatments like everolimus have the potential to prevent viral infections. As such, he emphasizes the need to choose epilepsy medications on an individual basis. In patients with well-controlled seizures, discontinuing or changing AEDs for the purpose of preventing infection is not recommended.

Dr Kuroda also noted that elective surgeries for patients with epilepsy should be postponed to prevent the spread of COVID-19. Urgent interventions should be performed under strict prevention and protection protocols. Healthcare providers and other medical professionals are encouraged to provide this information to patients with epilepsy to help curb anxiety and potentially reduce seizure frequency.

Reference

Kuroda N. Epilepsy and COVID-19: Associations and important considerations. Epilepsy Behav. 2020;108:107122. doi: 10.1016/j.yebeh.2020.107122.

View post:
Epilepsy and COVID-19: Connection and Considerations - Neurology Advisor

Global Neurology Software Market Register a xx% CAGR in Terms of Revenue By 2025: Epic, Athenahealth, Nextgen, healthfusion, Allscripts, Greenway…

Posted on by

A research report on the Global Neurology Software Market offers a detailed analysis about the market share, size, trends, and growth prospects. In addition, the report contains market volume with an accurate estimation offered in the report. The data offered in this report is gathered based on the latest industry news, trends, as well as opportunities. Moreover, the report comprises a complete market analysis and provider landscape with the help of SWOT analysis of the major service providers. This research report provides an extensive evaluation of the Neurology Software Market. The Global Neurology Software Market report is designed through the detailed qualitative insights, verifiable projections, and historical data about the Neurology Software Market size.

This study covers following key players:

EpicAthenahealthNextgenhealthfusionAllscriptsGreenway HealthPractice FusionBrainlabKareoBizmaticsAdvanced Data SystemsNueMD

Request a sample of this report @ https://www.orbismarketreports.com/sample-request/98665?utm_source=Pooja

In addition, the projections offered in this report have been derived with the help of proven research assumptions as well as methodologies. By doing so, the Neurology Software research study offers collection of information and analysis for each facet of the Neurology Software Market such as technology, regional markets, applications, and types. Likewise, the Neurology Software Market report offers some presentations and illustrations about the market that comprises pie charts, graphs, and charts which presents the percentage of the various strategies implemented by the service providers in the Global Neurology Software Market. In addition to this, the report has been designed through the complete surveys, primary research interviews, as well as observations, and secondary research.

Access Complete Report @ https://www.orbismarketreports.com/global-neurology-software-market-growth-analysis-by-trends-and-forecast-2019-2025?utm_source=Pooja

Market segment by Type, the product can be split into

Type IType II

Market segment by Application, split into

HospitalsCollege & Research InstitutesOther

Moreover, the Neurology Software Market report introduced the market through several factors such as classifications, definitions, market overview, product specifications, cost structures, manufacturing processes, raw materials, and applications. It also includes the major market conditions across the globe such as the product profit, price, production, capacity, demand, supply, as well as market growth structure. In addition, this report offers significant data through the SWOT analysis, investment return data, and investment feasibility analysis. The Neurology Software Market study also sheds light on the highly lucrative market opportunities that influences the growth of the global market. Moreover, the study offers a complete analysis of the market size, segmentation, and market share. Additionally, the Neurology Software report contains market dynamics such as market restraints, growth drivers, opportunities, service providers, stakeholders, investors, key market players, profile assessment, and challenges of the global market.

Some Major TOC Points:1 Report Overview2 Global Growth Trends3 Market Share by Key Players4 Breakdown Data by Type and ApplicationContinued

For Enquiry before buying report @ https://www.orbismarketreports.com/enquiry-before-buying/98665?utm_source=Pooja

About Us : With unfailing market gauging skills, has been excelling in curating tailored business intelligence data across industry verticals. Constantly thriving to expand our skill development, our strength lies in dedicated intellectuals with dynamic problem solving intent, ever willing to mold boundaries to scale heights in market interpretation.

Contact Us : Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

Go here to read the rest:
Global Neurology Software Market Register a xx% CAGR in Terms of Revenue By 2025: Epic, Athenahealth, Nextgen, healthfusion, Allscripts, Greenway...

COVID-19 and the Rise of Telemedicine for Chronic Neurological Disorders – Neurology Advisor

Posted on by

The coronavirus disease 2019 (COVID-19) outbreak has brought telemedicine into a new light with a rapid increase in the use of telemedicine and a recent viewpoint published in JAMA Neurology focused on the remote care of patients with chronic neurological disorders.

Bastiaan R. Bloem, MD, PhD, medical director of the Department of Neurology at Radboud University Medical Center, Nijmegen, the Netherlands explained that in light of the strong recommendation to avoid outpatient visits if possible, there has been a growing understanding that chronic neurological care can be safely delivered remotely and may be best delivered as close to the patients home as possible.

Episodic outpatient visit often provide an unrealistic perspective of the patients status and are not a reliable tool to identify rare complications or assess treatment outcomes that can fluctuate over time. On the other hand, home visits provide confidentiality, have the advantage of assessing the patients natural environment and can prevent the risks associated with long travels to the hospitals.

Telemedicine approaches can include videoconferencing for remote consultations, as well as remote monitoring using sensors that can be passive (occurring in the background) or active (asking patients to completed scheduled tasks).

Despite the potential advantages of telemedicine, it was not successful as anticipated with many stating that making a change in healthcare is a challenging task. However, the current COVID-19 global crisis has accelerated the use of telemedicine and remote consultation is becoming an increasingly attractive option across many healthcare systems. The experience of many patients and families has also been positive.

While previously there were many concerns regarding the use of telemedicine, the current crisis and the rise in telemedicine has helped to overcome many of the earlier objections against its use as it was shown that a simple neurological assessment can be performed remotely, the success was not limited to young patients but was also shown in many older adults, and reimbursement mechanisms were successfully implemented.

However, there are also challenges associated with this rapid rise in telemedicine, such as issues regarding privacy, security and participants confidentiality.

Telemedicine for chronic neurological disorders should become part of the new normal rather than the exception. Governments, health care systems, and payers should be encouraged to continue to embrace the new age of access from home, even after the pandemic passes, concluded Bloem.

Reference

Bloem BR, Dorsey ER, Okun MS. The Coronavirus disease 2019 crisis as catalyst for telemedicine for chronic neurological disorders [published online ahead of print, 2020 Apr 24]. JAMA Neurol. doi:10.1001/jamaneurol.2020.1452

View post:
COVID-19 and the Rise of Telemedicine for Chronic Neurological Disorders - Neurology Advisor

Branching Out in the Area of Genetic Neurology: Collaborating with Australian Clinical Trial Experts, Upcoming Webinar Hosted by Xtalks – PR Web

Posted on by

TORONTO (PRWEB) May 04, 2020

In this webinar, attendees will learn about the growing field of genetic neurology, with a focus on therapeutic discoveries, innovations in Phase I trials and leveraging the expertise of Australian-based experts and clinical trial providers.

Inspired by breakthroughs in the genetics of epilepsy, Massachusetts-based Praxis Precision Medicines is focused on both rare genetic epilepsies and more common central nervous system (CNS) disorders. To bring their innovations through the first phase of discovery and validation, Praxis sought the expertise of Australias largest Phase 1 clinical provider, Nucleus Network.

The discovery of gene variants that cause epilepsy has been led by a group of world-class academic researchers in Melbourne, Australia. It was this hotbed of epilepsy and genetics leaders that first attracted Praxis to Melbourne. However, when the company began to explore where to conduct their initial Phase 1 studies, they were grateful to find Nucleus Network in the same city, with just the right expertise and capabilities. Moreover, with a population of over 5 million, Melbourne has been an ideal location for Praxis studies. According to Praxis Senior Medical Director, Dr. Gabi Belfort, Nucleus Network offered an excellent solution for even highly technical studies involving the monitoring of brain waves by electroencephalography (EEG).

One critical study that was conducted at Nucleus involved measuring the pharmacodynamic effect (on EEG) of one of Praxis lead molecules in a multiple ascending dose study. The data collected in this study facilitated dose selection for a subsequent trial in patients with a psychiatric disease. Following on from the success of these initial trials, Praxis will be undertaking a titration study with Nucleus Network for another therapeutic, which may be useful for treating epilepsy or movement disorders.

Join Cameron Johnson, CEO, Nucleus Network and Gabi Belfort, MD, PhD, Senior Medical Director, Praxis Precision Medicines in a live webinar on Tuesday, May 19, 2020 at 4pm EST.

For more information or to register for this event, visit Branching Out in the Area of Genetic Neurology: Collaborating with Australian Clinical Trial Experts.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.comFor information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

See the original post here:
Branching Out in the Area of Genetic Neurology: Collaborating with Australian Clinical Trial Experts, Upcoming Webinar Hosted by Xtalks - PR Web

Rashes, headaches, tingling: the less common coronavirus symptoms that patients have – The Guardian

Posted on by

The World Health Organization lists the most common symptoms of Covid-19 as fever, tiredness and a dry cough. Others include a runny nose, sore throat, nasal congestion, pain, diarrhoea and the loss of sense of taste and/or smell. But there are also other more unusual symptoms that patients have presented.

Patients in several countries have reported rashes on their toes, resembling chilblains, in many cases unaccompanied by any of the usual symptoms of the virus. The condition has been dubbed Covid toe. The rashes can take the form of red or purple lesions and, despite the name, can be found on the side or sole of the foot, or even on hands and fingers. The European Journal of Pediatric Dermatology reported an epidemic of cases among children and adolescents in Italy. It said that unlike other rashes associated with coronavirus, it had not been previously observed.

Conjunctivitis has been a rare symptom in cases of Covid-19, with viral particles being found in tears. In the UK, the Royal College of Ophthalmologists and College of Optometrists says: It is recognised that any upper respiratory tract infection may result in viral conjunctivitis as a secondary complication, and this is also the case with Covid-19. However, it is unlikely that a person would present with viral conjunctivitis secondary to Covid-19 without other symptoms of fever or a continuous cough as conjunctivitis seems to be a late feature where is has occurred.

A peer-reviewed Spanish study, published in the British Journal of Dermatology last week, found that 6% of the 375 coronavirus cases examined involved livedo, the death of body tissue due to a lack of blood supply, or livedo, discolouration of the skin. The skin can become mottled and have purple or red patchy areas, which may appear in a lace-like pattern. In the study, it was generally found in older patients with more severe cases of Covid-19. However, this was not consistent across the board and necrosis was also found in some people with coronavirus who did not require hospitalisation.

A study of 214 patients in China, published in Jama Neurology last month, found that just over a third (36.4%) had experienced neurological symptoms such as dizziness or headaches, increasing to 45.5% in those with severe coronavirus infections. Commenting on the research, Prof Ian Jones, professor of virology at the University of Reading, said: It happens, but is generally not what coronaviruses do. At the moment neurological complications might best be considered a consequence of Covid-19 disease severity rather than a distinct new concern.

Some patients have complained about a tingling, fizzing or even burning sensation. Dr Waleed Javaid, the director of infection prevention and control at Mount Sinai hospital in New York, told Today.com it was likely the patients immune response to Covid-19 rather than the virus itself was causing such sensations. He said: Theres a widespread immune response that is happening. Our immune cells get activated so a lot of chemicals get released throughout our body and that can present or feel like theres some fizzing. When our immune response is acting up, people can feel different sensations I have heard of similar experiences in the past with other illnesses.

More here:
Rashes, headaches, tingling: the less common coronavirus symptoms that patients have - The Guardian

ORYZON First Quarter 2020 Results and Corporate Update Madrid Stock Exchange:ORY.MC – GlobeNewswire

Posted on by

MADRID, Spain and CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first quarter of 2020 and provided an update on recent developments.

Dr Carlos Buesa, Oryzons Chief Executive Officer, said, "Oryzon continued to advance its clinical programs in the first quarter. We are encouraged by the exciting signals of clinical efficacy observed in both our iadademstat oncology and vafidemstat neurology programs, combined with good safety and tolerability profiles.

During the last weeks of Q1 and into Q2 2020, the Covid-19 pandemic has impacted activities of pharma and biotech companies globally. As the company reported in an ad-hoc note released on April 17th, Oryzon has not canceled or postponed recruitment in ongoing clinical trials, however clinical operations have been adapted to protect the health of patients, their families and healthcare professionals, and to preserve the integrity of the trial data as much as possible. Also as previously disclosed, Oryzon is postponing the initiation of its vafidemstat Phase IIb trial in agitation-aggression in patients with borderline personality disorder (PORTICO trial) until lock-down conditions are eased sufficiently. To contribute to the global fight against the pandemic, Oryzon launched a Phase II clinical trial, named ESCAPE, in severe Covid-19 patients to prevent acute respiratory distress syndrome (ARDS). The trial was approved by the Spanish Drug Agency via an accelerated procedure as reported in an ad-hoc note released on April 24th.

First Quarter and Recent Highlights

Iadademstat in oncology:

Vafidemstat in neurological disease:

Financial Update: First Quarter 2020 Financial Results

Research and development (R&D) expenses were $4.3 million for the last 3 months ended March 31, 2020 compared to $2.6 million for the last 3 months ended March 31, 2019. The $1.7 million increase was driven primarily by expenses associated with advancing the companys clinical trials.

General and administrative expenses were $0.9 million for the last 3 months ended March 31, 2020 and for 3 months ended March 2019.

Net loss was $1.1 million for the last 3 months ended March 31, 2020, compared to net loss of $1.0 million for the last 3 months ended March 2019.

Cash, cash equivalents and marketable securities totaled $32.3 million as of March 31, 2020, compared to $32.7 million as of March 31, 2019.

About OryzonFounded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzons LSD1 program has rendered two compounds, vafidemstat and iadademstat, in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has offices in Spain and the United States. For more information, visit http://www.oryzon.com

FORWARD-LOOKING STATEMENTS This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words expects, anticipates, believes, intends, estimates and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisin Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forwardlooking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzons securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzons securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.

Read the original here:
ORYZON First Quarter 2020 Results and Corporate Update Madrid Stock Exchange:ORY.MC - GlobeNewswire

PEDIATRIC NEUROLOGY DEVICE Market: A Deep Dive Analysis of Various Regions and Strategies During Forecast Period 2020 2025 : lana , Inova Healthcare…

Posted on by

PEDIATRIC NEUROLOGY DEVICE Market 2020 Updated for the impact of COVID-19Chicago, United States,- Report Hive Research announces the release of the report PEDIATRIC NEUROLOGY DEVICE Market Research Report by Top Keyplayers, by Type, by Application, Global Forecast to 2025 Cumulative Impact of COVID-19

Latest update onPEDIATRIC NEUROLOGY DEVICE MarketAnalysis report published with extensive market research, PEDIATRIC NEUROLOGY DEVICE Market growth analysis, and forecast by 2025. This report is highly predictive as it holds the overall market analysis of topmost companies into the PEDIATRIC NEUROLOGY DEVICE industry. With the classified PEDIATRIC NEUROLOGY DEVICE market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The report highlights several significant features of the global PEDIATRIC NEUROLOGY DEVICE market encompassing competitive landscape, segmentation analysis, and industry environment. It shows the scope of the market and a brief overview of the definition and description of the product or service. The potential factors that can bring the market to the upward direction have been mentioned in the report. With this report, companies, as well as individuals interested in this report, will get proven valuable guidelines and direction so that they consolidate their position in the market. The report assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the PEDIATRIC NEUROLOGY DEVICE industry. Growth of the overall PEDIATRIC NEUROLOGY DEVICE market has also been forecasted for the period 2020-2025, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

PEDIATRIC NEUROLOGY DEVICE Market competition by top Manufacturers:<>

lana, Inova Healthcare System, Medtronic, The Nemours Foundation, Stryker, Boston Scientific, B.Braun Melsungen, Integra LifeSciences, St. Jude Medical

>>>>To know How COVID-19 Pandemic Will Impact This PEDIATRIC NEUROLOGY DEVICE Market| Download PDF Sample copy of the Report

The report provides insights on the following pointers:

NOTE: Our team is studying Covid-19 impact analysis on various industry verticals and Country Level impact for a better analysis of markets and industries. The 2020 latest edition of this report is entitled to provide additional commentary on latest scenario, economic slowdown and COVID-19 impact on overall industry. Further it will also provide qualitative information about when industry could come back on track and what possible measures industry players are taking to deal with current situation.

PEDIATRIC NEUROLOGY DEVICE Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including PEDIATRIC NEUROLOGY DEVICE market size, volume and value, as well as price data.

This study analysis was given on a worldwide scale, for instance, present and historical PEDIATRIC NEUROLOGY DEVICE growth analysis, competitive analysis, and also the growth prospects of the major regions. The report gives an exhaustive investigation of this market at country & regional levels, and provides an analysis of the industry trends in each of the sub-segments, from production, revenue and consumption. A quantitative and qualitative analysis of the main players in related regions is introduced, from the perspective of PEDIATRIC NEUROLOGY DEVICE production, PEDIATRIC NEUROLOGY DEVICE revenue, PEDIATRIC NEUROLOGY DEVICE consumption and PEDIATRIC NEUROLOGY DEVICE price.

According to the current situation, the official counts of cases and deaths from COVID-19 have passed 4,000,000 and 280,000 at the time of this report. Many government announced a plan on reopening the national economy, but many countries are still at the stage of rising. XYZResearch published a report for global PEDIATRIC NEUROLOGY DEVICE market in this environment.

In terms of revenue, this research report indicated that the global PEDIATRIC NEUROLOGY DEVICE market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of PEDIATRIC NEUROLOGY DEVICE industry comprises of Asia, North America, South America, Middle East and Africa, Europe, with the production and revenue data in each of the sub-segments.The lana aims at producing XX PEDIATRIC NEUROLOGY DEVICE in 2020, with XX % production to take place in global market, Inova Healthcare System accounts for a volume share of XX %.

At the upcoming analysis, this report discusses industrial policy, economic environment, in addition to the COVID-19 impact and cost structures of the industry. And this report encompasses the fundamental dynamics of the market which include drivers, opportunities, and challenges faced by the industry. Additionally, this report showed a keen market study of the main consumers, raw material manufacturers and distributors, etc.

PEDIATRIC NEUROLOGY DEVICE Market Classification by Types:

Neurosurgery DevicesNeurostimulatorCerebrospinal Fluid (CSF) Management Devices

PEDIATRIC NEUROLOGY DEVICE Market Size by End-user Application:

HospitalsHealthcare CentersNeurological Research Centers

Regional Analysis:The report comprises of regional development status, covering all the major regions of the world. This regional status shows the size (in terms of value and volume), and price data for the global PEDIATRIC NEUROLOGY DEVICE market. The development of the industry is assessed with information on the current status of the industry in various regions. Data type assessed concerning various regions includes capacity, production, market share, price, revenue, cost, gross, gross margin, growth rate, consumption, import, export, etc.

Regional coverage:North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Some Main Reasons For Purchasing This Report:

Readers of this report will receive in-depth knowledge about the market.

Updated statistics offered on the global PEDIATRIC NEUROLOGY DEVICE market report.

This report provides an insight into the market that will help you boost your companys business and sales activities.

It will help you to find prospective partners and suppliers.

It will assist and strengthen your companys decision-making processes.

The research report of the PEDIATRIC NEUROLOGY DEVICE market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the PEDIATRIC NEUROLOGY DEVICE market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the PEDIATRIC NEUROLOGY DEVICE Market growth opportunities in the industry.

Major Highlights from Table of contents are listed below for quick lookup into PEDIATRIC NEUROLOGY DEVICE Market report

In this report, Leading players of the global PEDIATRIC NEUROLOGY DEVICE Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global PEDIATRIC NEUROLOGY DEVICE Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global PEDIATRIC NEUROLOGY DEVICE Market. It also provides useful recommendations for new as well as established players of the global PEDIATRIC NEUROLOGY DEVICE Market.

Why Go For Report Hive Research?

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Get in Touch with Us :Report Hive Research500, North Michigan Avenue,Suite 6014,Chicago, IL 60611,United StatesWebsite: : https://www.reporthive.comEmail: [emailprotected]Phone:+1 312-604-7084

Go here to read the rest:
PEDIATRIC NEUROLOGY DEVICE Market: A Deep Dive Analysis of Various Regions and Strategies During Forecast Period 2020 2025 : lana , Inova Healthcare...

Neurologist talks about risk of blood clots, stroke, and heart attack associated with COVID-19 – fox8.com

Posted on by

Free download: How to talk to your kids about wearing a maskNews / 6 hours ago

One of our Gender Reveal families welcomes a girl!Syndication / 8 hours ago

AJ Petitti explains what you should be doing right now to get your garden ready to plantNews / 8 hours ago

Neurologist talks about risk of blood clots, stroke, and heart attack associated with COVID-19News / 9 hours ago

Tri-C teacher dresses in costumes to keep students engagedNews / 1 day ago

Local teachers make video to inspire and motivate students through online learningNews / 1 day ago

Doctor on reopening Ohio: 'This is not a return to business as usual'News / 1 day ago

Stork Report 4.22.20Syndication / 2 days ago

Cleveland's Own Allie LaForce and husband feed healthcare workers through #ProjectFrontlineNews / 4 days ago

'Be kind to one another': Cleveland Clinic nurse shares message with Northeast Ohio from New York CityNews / 4 days ago

'What I've seen is teamwork':Cleveland Clinic doctor talks about the people on the frontlines of coronavirus pandemicNews / 4 days ago

Helping those battling alcoholism during the coronavirus outbreakNews / 5 days ago

Read more:
Neurologist talks about risk of blood clots, stroke, and heart attack associated with COVID-19 - fox8.com

Effects of Hypertension on Cognitive Function Following Stroke – Neurology Advisor

Posted on by

While stroke survivors with higher systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements are more likely to have worse cognitive performance at 90 days, this association is most likely mediated by sociodemographic and clinical factors, according to study results published in the Journal of Stroke and Cerebrovascular Diseases.

Cognitive decline is commonly seen following stroke and was previously found to be associated with increased disability and mortality. While high blood pressure is associated with late-life cognitive impairment, there are no clear data on the association between blood pressure levels and poststroke cognitive decline. The goal of the current study was to investigate the associations between SBP, DBP, and antihypertensive medication use with cognitive function at 90 days after stroke.

The researchers used data from the Brain Attack Surveillance in Corpus Christi (BASIC) project, a population-based stroke surveillance project in Nueces County, Texas. All participants were required to have measurements of blood pressure and cognitive function at the 90-day in-person outcome assessment.

The study sample included 432 participants aged 45 years (median age 66 years, 45% female), most of them were diagnosed with an ischemic stroke and the median National Institutes of Health stroke score was 3.

The primary outcome was the modified Mini-Mental Status Examination (3MSE) and secondary outcomes included the Animal Fluency Test (AFT) to assess executive function and Trail Making Tests A and B divided by completion time to assess visuomotor tracking, information processing speed, divided attention, and cognitive flexibility.

While higher SBP and lower DBP each were significantly associated with lower 3MSE scores, following multiple adjustments for patient factors both did not remain independently associated with 3MSE. Similarly, higher SBP and lower DBP each were significantly associated with worse cognitive performance for AFT, Trails A, and Trails B, but these associations disappeared following adjustment for clinical factors, other than the association between DBP with worse Trails B scores.

Lower cognitive performance was associated with older age, less education, Mexican American ethnicity, diabetes, higher stroke severity, more depressive symptoms, and lower BMI.

Most stroke survivors with hypertension were adherent to anti-hypertensive medication (71%). While there was no association between nonadherence to antihypertensive medication with 3MSE scores, among hypertensive stroke survivors, nonadherence was associated with lower AFT scores, compared to those who adhered to the prescribed medication (adjusted difference, -1.21 points; 95% CI, -2.24 to -0.19; P=.02), but not other tests.

The study had several limitations, according to the researchers, including the cross-sectional design, relatively small sample size, exclusion of a large number of stroke patients due to missing data, limited data on stroke and structural brain features, measurement of blood pressure and assessment of the cognitive outcomes only at 90 days after stroke with no available data on the cognitive function at other time points.

Stroke survivors [blood pressure] levels were not associated with cognitive performance at 90 days independent of sociodemographic and clinical factors, conclude the researchers.

Reference

Levine DA, Galecki AT, Okullo D, et al. Association of blood pressure and cognition after stroke [published online May 1, 2020]. J Stroke Cerebrovasc Dis. doi:10.1016/j.jstrokecerebrovasdis.2020.104754

See the original post:
Effects of Hypertension on Cognitive Function Following Stroke - Neurology Advisor

Artax Biopharma Announces the Formation of Scientific Advisory Board to Advance Autoimmune Disease Therapy AX-158 – BioSpace

Posted on by

CAMBRIDGE, Mass., June 24, 2020 /PRNewswire/ --Artax Biopharma, Inc., a biotechnology company focused on transforming autoimmune disease treatment, today announces the formation of their Scientific Advisory Board (SAB). The SAB is comprised of experts in Immunology, Autoimmune Disease, and T Cell Signaling, and was formed to guide the company as it proceeds into future clinical trials with a first-in-class, oral small molecule autoimmune disease immunomodulator AX-158.

Artax Biopharma is poised to enter clinical trials with the small molecule AX- 158, a novel approach to treat multiple autoimmune diseases without causing the immunosuppression commonly associated with current autoimmune disease therapies.

Balbino Alarcn, PhD, Chairman of Artax's Scientific Advisory Board, commented, "I am privileged to lead Artax's Scientific Advisory Board, which mobilizes global leaders in Immunology, Autoimmune Disease, and T Cell Signaling. Collectively we are enthusiastic to collaborate on, and contribute to, important development initiatives related to Artax's innovative approach to autoimmune disease treatment."

"Artax Biopharma's Nck inhibitor AX-158 has shown impressive experimental biologic and mechanistic impact on T cell modulation - managing autoimmune disease without inducing the profound immunosuppression or interference with memory response associated with conventional or biological therapies," stated Dr. Lawrence Steinman, Stanford University Zimmerman Professor of Neurology and Neurosciences, Pediatrics, and Genetics and Scientific Advisory Board member.

"Convening a Scientific Advisory Board is a critical step as we accelerate our clinical development program," stated Artax Biopharma Chief Executive Officer Joseph Lobacki. "The clinical expertise and knowledge of these experts is unparalleled and will be instrumental in informing our development strategy across several autoimmune diseases."

The SAB will be comprised of five experts, and is being led by Professor Balbino Alarcn, PhD, co-founder of Artax Biopharma:

Balbino Alarcn, PhDDr. Alarcn is Program Director at the National Research Council of Spain (CSIC) and Head of the TCR-mediated Signal Transduction Laboratory.

Raif Geha, MDDr. Geha is the James L. Gamble Professor of Pediatrics at Harvard Medical School and Chief of the Allergy/Immunology/Rheumatology and Dermatology Division at Children's Hospital in Boston.

Menno de Rie, MDProf. de Rie is a board-certified dermatologist and vice-chair of the department of Dermatology of the Amsterdam University Medical Centres/ University of Amsterdam.

Lawrence Steinman, MDDr. Steinman is the George A. Zimmermann professor of Neurology and Neurological Sciences, Pediatrics, and Genetics at Stanford University.

Cox Terhorst, PhDDr. Terhorst is Chief of Immunology at Beth Israel Deaconess Medical Center and Professor at Harvard Medical School.

About ImmunomodulationA healthy immune system eliminates harmful foreign pathogens, while being tolerant of self-tissues and organs. When the immune system malfunctions, cells (T Cells) attack self-tissues and organs, causing autoimmune disease. Current autoimmune disease therapies suppress the immune system, helping to minimize these self-attacks, but also raise susceptibility to harmful foreign pathogens. Immunomodulation, the process in which the immune system reduces self-attacks while properly reacting to fight foreign pathogens, holds great potential for autoimmune disease.

About Artax-158AX-158 is a first-in-class, oral small molecule, preclinical immunomodulating agent in development for the treatment of autoimmune diseases. AX-158 employs a novel mechanism of action that selectively modulates, or adjusts, T cell responses that play a critical role in immune system function. By selectively inhibiting Nck, a protein, AX-158 selectively modulates self-directed T Cell activation which is a cause of autoimmune disease. Importantly, data suggest AX-158 is not immunosuppressive and does not impact the immune system's ability to mount a strong response to foreign pathogens and infections. Further, AX-158's ability to modulate T cell responses allows the possibility to broadly target several autoimmune diseases, therefore potentially transforming autoimmune disease treatment.

About Artax BiopharmaArtax Biopharma is a biotechnology company transforming autoimmune disease treatment. Artax is a life science industry leader in autoimmune disease immunomodulation science, developing an innovative small molecule approach to treat autoimmune disease that modulates the immune system to both treat autoimmune disease and allow the body to fight foreign pathogens. The company is examining a first-in-class oral immunomodulating agent as a new way to treat multiple autoimmune diseases without causing the immune suppression commonly associated with currently available autoimmune disease therapies. For more information, please visit http://www.artaxbiopharma.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/artax-biopharma-announces-the-formation-of-scientific-advisory-board-to-advance-autoimmune-disease-therapy-ax-158-301082763.html

SOURCE Artax Biopharma

Read more from the original source:
Artax Biopharma Announces the Formation of Scientific Advisory Board to Advance Autoimmune Disease Therapy AX-158 - BioSpace

Eisai will shift U.S. HQ to New Jersey ‘bio-ecosystem’ in move to boost oncology, neurology portfolios – FiercePharma

Posted on by

Japanese drugmaker Eisai has established asolid foothold in the U.S. market and found some success with its Merck & Co.-partnered oncology med Lenvima. And alongside BIogen, it's in the FDA queue for a landmark decision in Alzheimer's disease.

But Eisai'sstateside ambitions are broader than thatand as if to illustrate that point, the company is plotting a new U.S. headquarters on a high-tech New Jersey campus.

Eisai will relocateits U.S. headquarters from Woodcliff Lake, New Jersey, to a 15-story complex at the ON3 "bio-ecosystem" in Nutley, New Jersey, by the end of 2021,the Tokyo-based drugmaker said Tuesday.

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

Eisai will be the first biopharma tenant at the 116-acre site,formerly Roche'sU.S. headquarters, alongside residents from the healthcare, R&D and diagnostics fields. All told, Eisai will ship 1,200 of its corporate and R&D employees to the site, which the drugmaker called "technologically advanced and cutting edge."

The move will give Eisai the opportunity to collaborate outside biopharma to boost its oncology, Alzheimer's disease and neurological portfolios, the company said. The location in a brand-new hub will also help Eisai recruit talented employees, a spokesperson said.

Eisai's relocation comes as the Japanese drugmaker works to boost its top-sellingoncology med Lenvima, which has found a promising partnership with Merck's Keytrudaalong with its share of setbacks.

Meanwhile, the drugmaker is also working with partner Biogen on controversial Alzheimer's drug aducanumab, which the FDA accepted for priority review last week.The agency expects to decide the fate of the treatment by March 7.

RELATED:Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light

That was a big loss for the duo, which still has just one FDA approval to its credit inendometrial carcinoma.The partners hoped an approval would put themup againstRoches pairing of immuno-oncology agent Tecentriq and anti-VEGF drug Avastin, which recently scoredan FDA nod in first-line liver cancer with gold-standard data showing they could help patients live longer.

The two companies are stilltesting the Keytruda-Lenvima combo as a first-line liver cancer therapy in the phase 3 Leap-002 study, which isfully enrolled.

RELATED:Eisai preps for launch with insomnia med Dayvigo after buying out Purdue

Meanwhile, Eisai has worked to flesh out its neurology business, scoring an FDA approval in December for Dayvigo, an insomnia castoff from Purdue Pharma.

Eisai took full ownership of Dayvigoin May 2019 after itbought outPurdue's stake in the drug in 2015.The drug is an orexin receptor antagonist that works by targeting the wake center of the brain, according to EisaiCEO and president of itsglobal neurology businessIvan Cheung, who called the approval "very exciting" at the time.

Read more from the original source:
Eisai will shift U.S. HQ to New Jersey 'bio-ecosystem' in move to boost oncology, neurology portfolios - FiercePharma

Social Isolation Tied to Higher Risk of CV Events, Death – Medscape

Posted on by

Social isolation is associated with an increased risk of a cardiovascular event of more than 40%, and of all-cause mortality approaching 50%, new research suggests.

"These results are especially important in the current times of social isolation during the coronavirus crisis," Janine Gronewold, PhD, University Hospital in Essen, Germany, told a press briefing.

The mechanism by which social isolation may boost risk for stroke, myocardial infarction, or death isn't clear, but other research has shown that loneliness or lack of contact with close friends and family can affect physical health, said Gronewold.

The findings were presented at the sixth Congress of the European Academy of Neurology (EAN) 2020, which transitioned to a virtual/online meeting because of the COVID-19 pandemic.

For this new study, researchers analyzed data from 4139 participants, ranging in age from 45 to 75 years (mean 59.1 years), who were recruited into the large community-based Heinz Nixdorf Recall (HNR) study. The randomly selected study group was representative of an industrial rural area of Germany, said Gronewold.

Study participants entered the study with no known cardiovascular disease and were followed for a mean of 13.4 years.

Investigators collected information on three types of social support: instrumental (getting help with everyday activities such as buying food), emotional (provided with comfort), and financial (receiving monetary assistance when needed).

They also looked at social integration (or social isolation) using an index with scores for marital status, number of contacts with family and friends, and membership in political, religious, community, sports, or professional associations.

Of the total, 501 participants reported a lack of instrumental support, 659 a lack of emotional support, and 907 a lack of financial support. Over 300 (309) lacked social integration, defined by the lowest level on the social integration index.

Participants were asked annually about new cardiovascular events, including stroke and myocardial infarction. Over the follow-up period, there were 339 such events and 530 deaths.

After adjustment for age, sex, and social support, the analysis showed that social isolation was significantly associated with an increased risk of cardiovascular events (hazard ratio [HR], 1.44; 95% CI, 0.97-2.14) and all-cause mortality (HR, 1.47; 95% CI, 1.09-1.97).

The new research also showed that lack of financial support was significantly associated with increased risk for a cardiovascular event (HR, 1.30; 95% CI, 1.01-1.67).

Additional models that also adjusted for cardiovascular risk factors, health behaviors, depression, and socioeconomic factors, did not significantly change effect estimates.

"Social relationships protect us from cardiovascular events and mortality, not only via good mood, healthy behavior, and lower cardiovascular risk profile," commented Gronewold. "They seem to have a direct effect on these outcomes."

Having strong social relationships is as important to cardiovascular health as classic protective factors such as controlling blood pressure and cholesterol levels, and maintaining a normal weight, said Gronewold.

The new results are worrying and are particularly important during the current COVID-19 pandemic, as social contact has been restricted in many areas, said Gronewold.

It's not yet clear why people who are socially isolated have such poor health outcomes, she added.

Gronewold has reported no relevant financial relationships.

Congress of the European Academy of Neurology (EAN) 2020. Abstract 2369. Presented May 22, 2020.

For more Medscape Neurology news, join us on Facebook and Twitter.

Link:
Social Isolation Tied to Higher Risk of CV Events, Death - Medscape

Asia Pacific, the rare neurological disease treatment market, is anticipated to reach US$ 2,437.02 Mn in 2027 from US$ 1,225.38 Mn in 2019 -…

Posted on by

New York, May 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Asia Pacific Rare Neurological Disease Treatment Market to 2027 - Regional Analysis and Forecasts by Indication ; Drug Type ; Distribution Channel ; Mode of Administration and Country" - https://www.reportlinker.com/p05894521/?utm_source=GNW Restraining factors, such as higher cost of rare neurological disease treatments likely to damage the growth of the market in the coming years.

On the other hand, artificial intelligence for the treatment of rare neurological diseases is expected to have a positive impact on the growth of the Asia Pacific rare neurological disease treatment market in the coming years.

A large group of rare diseases that have inefficient diagnoses and treatments are the neurological disease.These diseases target the nervous system, which include the brain, spinal cord, and all the nerves that run throughout the human body.

There is no surety regarding the onset of the diseases; some can strike during childhood, whereas others can affect even highly aged people.

In the world of medicine, rare neurological diseases represent significant burden on health systems in terms of disease diagnosis, treatment, and management.Some of the majorly observed rare neurological diseases comprises narcolepsy, amyotrophic lateral sclerosis, Alzheimers disease, multiple sclerosis, spinal muscular atrophy (SMA), Duchenne muscular dystrophy, and others.

According to a data published in neurological disorders report by World Health Organisation (WHO), most people with dementia are living in developed countries: by 2040, 60 percent in 2001 increased to an estimated 71 percent. Growth rates are not uniform; numbers are expected to rise by 100 percent in developed countries between 2001 and 2040, but by more than 300 percent in China, India and neighboring countries in South-East Asia and the Western Pacific.

Over the past few decades, various research and developmental works have been carried out pertaining to the diagnosis and management of rare neurological diseases.Advancements in healthcare systems and modernizing diagnostic systems are likely to enhance the screening operation for rare neurological diseases.

Additionally, increasing prevalence of rare neurological diseases is expected to drive the growth of the rare neurological disease treatment market during the forecast period.

In 2019, the Alzheimers disease accounted for the largest market share in the Asia Pacific rare neurological disease treatment market.Alzheimers disease is a progressive disease and a type of dementia, and the condition is characterized by eating and death of brain cells.

It is characterized by symptoms such as reduced thinking, memory loss, and lacking behavioural sense.These symptoms get worse over time and highly reduce the independently for daily routine.

The disease accounts for nearly 60% to 80% of all dementia cases.It is widely seen among the aging population.

The disease accounts for nearly 60% to 80% of all dementia cases. It is widely seen among the aging population. For instance, In 2012, Alzheimers Asia Pacific reports that prevalence of AD in China has been found to range between 7 per 1000 people to 66 per 1000 individuals.

In 2019, the biologics segment, held the most significant market share of the rare neurological disease treatment market by the drug type.This segment is also anticipated to be the fastest growing segment of the market in 2027, owing to the increasing neurological disorders, coupled with increasing robust hospital infrastructure and advancements in medicines, has enabled people for various treatments for the deadliest diseases.

Hence, the segment is anticipated to witness growth at a significant rate during the forecast period.

Some of the significant primary and secondary sources for cold plasma equipment included in the report are World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA) and National Institute of Health (NIH).Read the full report: https://www.reportlinker.com/p05894521/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the original post here:
Asia Pacific, the rare neurological disease treatment market, is anticipated to reach US$ 2,437.02 Mn in 2027 from US$ 1,225.38 Mn in 2019 -...

Coronavirus Patients Are Reporting Neurological Symptoms. Here’s What You Need to Know – ScienceAlert

Posted on by

As case numbers of COVID-19 continue to rise around the world, we are starting to see an increasing number of reports of neurological symptoms. Some studies report that over a third of patients show neurological symptoms.

In the vast majority of cases, COVID-19 is a respiratory infection that causes fever, aches, tiredness, sore throat, cough and, in more severe cases, shortness of breath and respiratory distress.

Yet we now understand that COVID-19 can also infect cells outside of the respiratory tract and cause a wide range of symptoms from gastrointestinal disease (diarrhoea and nausea) to heart damage and blood clotting disorders. It appears that we have to add neurological symptoms to this list, too.

Several recent studies have identified the presence of neurological symptoms in COVID-19 cases. Some of these studies are case reports where symptoms are observed in individuals.

Several reports have described COVID-19 patients suffering from GuillainBarr syndrome. GuillainBarr syndrome is a neurological disorder where the immune system responds to an infection and ends up mistakenly attacking nerve cells, resulting in muscle weakness and eventually paralysis.

Other cases studies have described severe COVID-19 encephalitis (brain inflammation and swelling) and stroke in healthy young people with otherwise mild COVID-19 symptoms.

Larger studies from China and France have also investigated the prevalence of neurological disorders in COVID-19 patients. These studies have shown that 36 percent of patients have neurological symptoms.

Many of these symptoms were mild and include things like headache or dizziness that could be caused by a robust immune response. Other more specific and severe symptoms were also seen and include loss of smell or taste, muscle weakness, stroke, seizure and hallucinations.

These symptoms are seen more often in severe cases, with estimates ranging from 46 percent to 84 percent of severe cases showing neurological symptoms. Changes in consciousness, such as disorientation, inattention and movement disorders, were also seen in severe cases and found to persist after recovery.

SARS-CoV-2, the coronavirus that causes COVID-19, may cause neurological disorders by directly infecting the brain or as a result of the strong activation of the immune system.

Recent studies have found the novel coronavirus in the brains of fatal cases of COVID-19. It has also been suggested that infection of olfactory neurons in the nose may enable the virus to spread from the respiratory tract to the brain.

Cells in the human brain express the ACE2 protein on their surface. ACE2 is a protein involved in blood pressure regulation and is the receptor the virus uses to enter and infect cells. ACE2 is also found on endothelial cells that line blood vessels.

Infection of endothelial cells may allow the virus to pass from the respiratory tract to the blood and then across the blood-brain barrier into the brain. Once in the brain, replication of the virus may cause neurological disorders.

SARS-CoV-2 infection also results in a very strong response by the immune system. This immune response may directly cause neurological disorders in the form of GuillainBarr syndrome. But brain inflammation might also indirectly cause neurological damage, such as through brain swelling. And it's associated with though doesn't necessarily cause neurodegenerative diseases such as Alzheimer's and Parkinson's.

SARS-CoV-2 is not unique in being a respiratory virus that can also infect the brain. Influenza, measles and respiratory syncytial viruses can all infect the brain or central nervous system and cause neurological disease.

Other coronaviruses have also been found to infect the brain and cause neurological disorders.

The related seasonal coronavirus, HCoV-OC43, typically causes very mild respiratory symptoms but can also cause encephalitis in humans. Similarly, the coronavirus that causes MERSand the 2003 SARS virus can cause severe neurological disorders.

Respiratory viruses getting into the brain is thankfully a rare occurrence. But with millions of COVID-19 infections worldwide, there is the risk of significant neurological disease, especially in severe cases.

It is important to be aware of the possibility of neurological manifestations of COVID-19, both during acute illness as well as the possibility of long-term effects. This also highlights the continued importance of preventing viral transmission and identifying those who are, and have been, infected.

Jeremy Rossman, Honorary Senior Lecturer in Virology and President of Research-Aid Networks, University of Kent.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Continue reading here:
Coronavirus Patients Are Reporting Neurological Symptoms. Here's What You Need to Know - ScienceAlert

UPDATED: Praxis Precision Medicines launches with $100M and bold sights on long-evasive neurological disorders – Endpoints News

Posted on by

Its going to be the era of neuroscience, Roche CEO Bill Anderson declared on stage at the JP Morgan Healthcare Conference in January. The field, he said, had the potential to be in the 20s what oncology was for the last decade.

Five months into that decade, a new biotech is emerging from stealth mode with large investments from Blackstone and two drugs already in Phase II, one of them nearing a pivotal trial. Called Praxis Precision Medicines, since 2016 its raised $100 million with Novo Holdings, Vida Ventures and Eventide also chipping in to back a bet that, by finding the underlying cause of rare neurological diseases, they could find and treat mechanisms behind more common ones.

For all Andersons optimism about the future, though, Praxis emerges at a tough time for neuroscience-focused biotechs. Much of the rest of Big Pharma has all but abandoned the field. The last major piece of neuro-news of the previous decade was the announcement, in December, that Sage Therapeutics vaunted drug for major depressive disorder had failed a large trial, a readout that has since cost the company $6 billion in market cap and induced them to cut more than half their staff. Praxiss lead drug goes after the same indication.

Its a challenging field, Praxis CEO Marcio Souza acknowledged in an interview.

The company began as an effort to findde novomutations that caused epilepsy the spontaneous genetic malfunctions that cause the disease in patients who did not inherit it from their parents. The search turned up, among other things, a gene that affects calcium channels in the brain. But instead of trying to fix that mutation, they used that information to figure out how that channel and how that channel falling out of balance, with neurons firing too much or too little played a role in other diseases.

What became quite clear is that when you were looking beyond just the pure mutations we were all talking about imbalances in a given part of the brain, and normally as it relates to a specific channel, Souza said.A lot of people jumped in the past from mutation correcting that mutation, or correcting the genetic defect. What were doing differently is looking into how that manifests and attempting to correct the actual manifestation.

The result was PRAX-944, a T-type calcium channel blocker that is in the early stages of development for rare forms of genetic epilepsy, but which the company is more aggressively taking forward in essential tremor, one of the more common neurological conditions. They expect to have Phase II proof-of-concept results before the end of the year.

The lead program, though, is PRAX-114, a depression drug. The overlapping indications here are perimenopausal depression, a relatively rare condition compared with major depressive disorder. Despite the vast medical need and market, scientists have struggled for years leading up to Sages flop to build better anti-depressants.

Praxis hopes to have an answer on their drug soon, with plans to enter a pivotal trial before the end of the year. The drug works by allosterically targeting GABAa, the neurotransmitter implicated in a long list of disorders and targeted head-on by benzodiazepines. Souza said the new trial will try to track patients as they would use it in their daily lives, hoping to show what he says they saw in Phase II: a safe and quick drug.

They have the right safety profile, Souza said. Most of the issue is not only with the efficacy, but with the safety of these compounds. And we think 114 has that balance.

Here is the original post:
UPDATED: Praxis Precision Medicines launches with $100M and bold sights on long-evasive neurological disorders - Endpoints News

What We Know About Multiple Sclerosis and COVID-19 – Medscape

Posted on by

Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

This transcript has been edited for clarity.

Hello. I'm Dr Steven Krieger, a neurologist at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis (MS) at Mount Sinai in New York, reporting for Medscape on the care of MS patients amidst the COVID-19 pandemic.

COVID-19 has impacted every one of us. Of course, we've been counseling our patients to observe stringent precautions: sheltering in place, maintaining effective home quarantine, practicing hand hygiene, wearing masks outside the home per the Centers for Disease Control and Prevention's recommendation, and encouraging social connectedness to prevent isolation during this time of physical distancing. But what else can we do specifically for our patients with MS?

Mount Sinai and many other institutions treating patients with MS have migrated all patient care to virtual and telehealth to try to minimize their exposure to the health system during this time. We're all developing clever ways to perform neurologic exams via video visits and have patients collect and report their own data. If you have any tips on how you're doing this in your own practice, please do add them in the comments section so everyone can benefit from your experience.

Our psychologists have also been holding video support groups for our patients to try to provide remote counseling and address the anxiety that everyone's feeling. We're trying to keep patients with MS from emergency department or urgent care exposure unless it's truly necessary.

In this new setting of COVID-19, we've established a higher threshold for treating MS relapses with steroids. If steroids must be used for a particularly debilitating relapse, we're trying to use oral preparations1250 mg of prednisone a day for 3-5 days with gastrointestinal prophylaxisso that patients can administer them at home and avoid intravenous treatment and nurse visits whenever possible.

There is yet no evidence that MS makes patients more susceptible to this infection. We're all incredibly susceptible to it. There's also no evidence that people with MS have a more severe experience of COVID-19; however, of course, disability is an important comorbidity.

Thankfully, there is also little evidence to date of increased infection susceptibility or risk for patients treated with disease-modifying therapies (DMTs). Whenever possible, our practice has been to not interrupt medication out of concern for COVID-19 and to counsel patients as such. We have to remain vigilant to the risk for disease rebound when DMTs are stopped, particularly the sphingosine 1-phosphate (S1P) modulators or natalizumab.

Sometimes we are choosing to delay infusions to minimize patients' risk of being exposed to the virus at a treatment center. Remember that natalizumab infusions can be safely delayed typically by about 1-2 weeks for extended-interval dosing. For patients with relapsing-remitting MS, we feel that ocrelizumab can probably be safely delayed by perhaps a month or 2 months without real risk for recurrent disease activity. Patients with primary progressive MS on ocrelizumab may be older, with more comorbidities and disability. Therefore, we've typically been trying to delay those infusions until the worst of the COVID-19 crisis, at least in this region, has begun to pass.

Many infusion centers may have limited resources as their nurses and other staff are redeployed for COVID-directed care. As such, trying to decrease the burden on patient centers during this time may be appropriate.

In recent months, we've really fielded two different waves of phone calls and inquiries from our patients with MS. In February and March, we had innumerable calls from people asking what they should do in advance out of concern for this disease. In April, those calls have since changed to ask what they should do now that they have COVID-19. Those are challenging conversations, because COVID-19 affects people in such a heterogeneous way, both in terms of symptoms and severity.

If one of our patients with MS develops COVID-19, we've begun counseling them that they can, for example, hold their interferon injections to avoid additional flu-like symptoms during the acute infection. We could counsel patients to hold S1P modulators like fingolimod during a prolonged episode of high fever, but hopefully not beyond the 14-day period, after which new first-dose observation would be needed again. Again, this strategy aims to prevent an extended amount of exposure in the medical system.

We are recommending that patients hold their infusion therapies at least until a week or so after their primary COVID-19 symptoms and fever have resolved. As previously noted, extended-interval dosing for natalizumab is likely both safe and effective.

And, of course, for any patient with symptoms of COVID-19, it's crucial to counsel them to seek urgent care if they develop difficulty breathing or significant shortness of breath.

There is a very nice review published this April in Neurology by Brownlee and colleagues looking at the implications of using DMTs in people with COVID-19. There's also research looking at the potential for S1P modulators like fingolimod to prevent acute respiratory distress syndrome in aggressively worsening COVID-19. The hope there is that this immunomodulatory strategy might prevent the potentially devastating influx of lymphocytes into the pulmonary compartment.

Clinical data on people with MS contracting COVID-19 are also now being collected by several different research consortia around the world. In pulling together this information, they are hoping to provide crucial information that we can use to guide our treatment decisions.

Comi and colleagues presented data via the National Multiple Sclerosis Society (NMSS), I believe with a publication forthcoming, from three Italian centers at the beginning of this crisis. They looked at 150 patients with MS and COVID-19, 90% of whom remained at home. Only a small handful required intensive care unit admission and critical care. There was no trend for worse outcomes for MS patients on individual DMTs. As with the general population, however, older patients had a more severe course of COVID-19.

The International Women in Multiple Sclerosis group has been gathering the latest data on their website, listing best practices for MS patients in the era of COVID-19. And a joint effort from the NMSS and the Consortium of Multiple Sclerosis Centers, called COViMS (COVID-19 Infections in MS & Related Diseases), is going to aggregate data for MS patients with COVID that we can all learn something from in the weeks and months to come.

As we await these forthcoming data and continue to provide care for patients with neurologic disease and with MS in particular, I'd like to offer a little reminder of the two essential tools we have at our disposal: effective hand hygiene and masks to prevent transmission of this disease. We need to protect ourselves as we protect our patients. Stay safe, everyone.

Reporting from New York City for Medscape, I'm Steven Krieger.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

See more here:
What We Know About Multiple Sclerosis and COVID-19 - Medscape

COVID-19 may harm both the brain and the lungs – PhillyVoice.com

Posted on by

As doctors gain a better understanding of how the coronavirus attacks the human body, the list of possible symptoms caused by an infection continues to grow. Itnow appears to include neurological damage.

Reportsfrom China, where the pandemic originated, and other coronavirus hotspots, including the United States, suggest that the coronavirus can spread to the brain, potentially leading to a seizure, stroke or encephalitis.

In response,theU.S. Centers for Disease Control and Preventionhas added "new confusion or inability to arouse" to the list of emergency warning signs for COVID-19.

The most common symptoms are cough, fever, fatigue and difficulty breathing. OtherCOVID-19 patients have experienced headache, vomiting, nausea and loss of sense of smell and taste.

But there is growing concern about the coronavirus's ability to harm the brain.

According to Dr. Lin Mei, director of the Cleveland and Brain Health Initiative, the coronavirus can travel to the brain from the nasal cavity, through the bloodstream or by attaching itself to nerve terminals.

More research is needed to determine whether the coronavirus directly causes neurological symptoms by breaching the blood-brain barrier or if those symptoms are a side effect of the virus attacking other systems in the body.

For instance, does the coronavirusdirectly cause a stroke or does the infection lead to a spike in blood pressure, which then triggers a stroke?

Henry Ford Health System doctors recently reported a case of encephalitis in a 58-year-old Detroit woman who tested positive for COVID-19. She developed acute necrotizing encephalitis, a central nervous system infection more commonly seen in young children.

Her symptoms began with just a fever, cough and muscle aches. But a few days later, she started experiencing confusion and disorientation. She was rushed to the emergency department by ambulance and was tested for the flu and COVID-19. The flu test came back negative, the rapid COVID-19 test positive.

Her care team suspected she had encephalitis and ordered imaging scans. The MRI scan showed abnormal lesions inboth the thalami and temporal lobes of the brain, which regulate consciousness, sensation and memory function.

"This is significant for all providers to be aware of and looking out for in patients who present with an altered level of consciousness,"Dr. Elissa Fory, a Henry Ford neurologist saidin a statement."We need to be thinking of how we're going to incorporate patients with severe neurological disease into our treatment paradigm.This complication is as devastating as severe lung disease."

Frank Carter, a 82-year-old man in Tennessee, also experienced neurological symptoms related to COVID-19, NBC Newsreported. Besides some nausea and vomiting, the first indicator of the infection was delirium, according to his daughter, who is a nurse. He died within a week.

There have been neurological symptoms in COVID-19 patients in China as well.

At the Union Hospital of Huazhong University of Science and Technology in Wuhan, 36.4% of COVID-19 patients developed neurological issues,according to a study published in the journalJAMA Neurology.For some, the neurological symptoms even showed up before the cough and fever.

"We've been telling people that the major complications of this new disease are pulmonary, but it appears there are a fair number of neurological complications that patients and their physicians should be aware of," Dr. Andrew Josephson, editor of JAMA Neurology, wrote in a commentary to the study.

Dr. E. Wesley Ely, a professor of medicine and critical care at Vanderbilt University Medical Center is collaborating with the Critical Illness, Brain Dysfunction and Survivorship Center in studying post-mortem brain tissue to better understand how COVID-19 affects the neurological system.

The researchers will measure different regions of the brain to see whether they have shrunk. They also will look for damage to neurons and evidence of the proteins associated with dementia and Alzheimer's disease. Carter's brain was the first to be donated to the project.

Health officials say that it is important for people to watch for sudden cognitive changes in family members so they can more quickly get the help they might need.

See more here:
COVID-19 may harm both the brain and the lungs - PhillyVoice.com

Satsuma Pharmaceuticals to Host Key Opinion Leader Event: STS101 and the Acute Treatment of Migraine – Yahoo Finance

Posted on by

SOUTH SAN FRANCISCO, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (STSA), a clinical-stage biopharmaceutical company, announced today that it will host a Key Opinion Leader (KOL) event discussing STS101 and the acute treatment of migraine on Tuesday, May 5, 2020 at 12:00pm Eastern Time.

The event will feature presentations by headache medicine specialists Jessica Ailani, MD, from MedStar Georgetown Headache Center, and Alan Rapoport, MD, from The David Geffen School of Medicine at UCLA, addressing the current treatment landscape for the acute treatment of migraine, unmet needs, and potential roles for Satsumas product candidate, STS101. As well, Satsuma's Chief Medical Officer, Detlef Albrecht, MD, will review the design of the ongoing STS101 EMERGE Phase 3 pivotal efficacy and safety trial. Following presentations, Drs. Ailani, Rapoport, Albrecht and members of Satsumas management team will be available to answer questions from the audience.

STS101 is an investigational product designed to make the well-established anti-migraine benefits of dihydroergotamine (DHE) more broadly accessible to people with migraine. STS101 is a simple-to-use, nasal-route DHE product featuring easy and quick self-administration (within a matter of seconds) and a pharmacokinetic profile similar to DHE administered by intramuscular injection, which Satsuma believes is necessary for achieving optimal DHE efficacy. In developing STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, pre-filled and ready-to-administer non-injectable DHE product candidate that it believes could, if approved, better meet the needs of people with migraine than current and development-stage DHE products. STS101 has undergone extensive preclinical development, completed a Phase 1 clinical trial, and is currently in Phase 3 development.

Jessica Ailani, MD, is a Professor of Clinical Neurology and Director of the MedStar Georgetown Headache Center at MedStar Georgetown University Hospital in Washington, DC. She received her medical degree from the Stony Brook University School of Medicine in New York, followed by an internship at Winthrop University Hospital in Mineola, New York. Dr. Ailani subsequently completed a residency and Chief Residency in Neurology at NYU Langone Medical Center in New York, New York, followed by a fellowship in Headache Medicine at Thomas Jefferson University in Philadelphia, Pennsylvania. She is board-certified in Neurology with subspecialty certification in Headache Medicine.

Dr. Ailani is a fellow of the American headache society and of the American Academy of Neurology. She holds a position on the board of the American Headache Society as a member at large. For AHS, Dr. Ailani is a co-chair of the Practice management committee and is on the scientific and Scottsdale program planning committees. Dr. Ailani is Section Editor of Unusual Headache Syndromes for Current Pain and Headache Reports and a reviewer for several professional journals. Dr. Ailani has presented nationally on topics surrounding headache medicine.

Alan Rapoport, MD is a Clinical Professor of Neurology at The David Geffen School of Medicine at UCLA, Los Angeles, California, where he teaches medical students, neurology residents and fellows. He is a Past President of the International Headache Society (IHS) and the founder and Director-Emeritus of The New England Center for Headache, in Stamford, Connecticut. Board-certified in Neurology and Headache Medicine, he has co-authored more than 300 articles,10 books, as well as multiple chapters and posters on headache and other neurological diseases.

Dr. Rapoport is the Co-Founder and CEO of BonTriage, an IT company in Silicon Valley, California, dedicated to helping patients and doctors around the globe by collecting detailed patient histories on line and linking with an app that monitors patient progress and outcomes. Dr. Rapoport has served on the Board of Directors of the American Headache Society (AHS) and is the immediate past President of the Fairfield County Neurological Society (Connecticut), the Founding President of the Headache Cooperative of New England (HCNE), the Founding Director of the Headache Cooperative of the Pacific (HCOP). He is the director of the headache day at the annual Controversies in Neurology (CONy) which was held in Madrid in 2019 and will be held in London in October 2020.

Story continues

About Satsuma Pharmaceuticals and STS101Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. In developing STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, non-injectable DHE product that can be rapidly self-administered in a matter of seconds. The Company believes STS101 would, if approved, be an attractive migraine treatment option for many patients and may enable a larger number of people with migraine to realize the long-recognized therapeutic benefits of DHE therapy. STS101 has undergone extensive pre-clinical development, completed a Phase 1 clinical trial, and is currently in Phase 3 development.

Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit http://www.satsumarx.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements concerning the business, operations and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the Company), as well as the Companys plans, objectives and expectations for its business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as aim, anticipate, assume, believe, contemplate, continue, could, due, estimate, expect, goal, intend, may, objective, plan, predict, potential, positioned, seek, should, target, will, would, and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about the Companys expectations regarding the potential safety and efficacy of STS101; the potential benefits of STS101, if approved; and the likelihood of regulatory filings and approvals for STS101. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The Companys actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Companys Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Companys ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of STS101; the results of preclinical and clinical studies may not be predictive of future results; the risk that the COVID-19 worldwide pandemic may negatively impact the development of STS101; the unpredictability of the regulatory process; regulatory developments in the United States and foreign countries; the costs of clinical trials may exceed expectations; and the Companys ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

This press release discusses STS101, a product candidate that is in clinical development, and which has not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of STS101 for the therapeutic use for which STS101 is being studied.

INVESTOR AND CORPORATE CONTACTS:

Corey Davis, PhDLifeSci Advisors, LLCcdavis@lifesciadvisors.com

Tom ONeil, Chief Financial OfficerSatsuma Pharmaceuticals, Inc.tom@satsumarx.com

Read more:
Satsuma Pharmaceuticals to Host Key Opinion Leader Event: STS101 and the Acute Treatment of Migraine - Yahoo Finance